Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.92 +2.3%	$186.85	$163.52 ▼ $218.66	$327.88B	0.48	6.25 million shs	5.94 million shs
ABT Abbott Laboratories	$136.21 +0.1%	$133.03	$99.71 ▼ $141.23	$236.64B	0.73	6.15 million shs	5.34 million shs
MRK Merck & Co., Inc.	$81.75 +3.3%	$79.14	$73.31 ▼ $129.93	$198.77B	0.39	13.20 million shs	21.80 million shs
NVS Novartis	$123.06 +1.7%	$114.40	$96.06 ▼ $123.82	$255.62B	0.59	1.58 million shs	1.43 million shs
PFE Pfizer	$25.03 +3.3%	$23.56	$20.92 ▼ $31.54	$137.81B	0.58	41.52 million shs	59.11 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+2.15%	+1.02%	+0.15%	-9.84%	+8.33%
ABT Abbott Laboratories	+1.26%	+2.12%	+1.80%	+3.33%	+30.97%
MRK Merck & Co., Inc.	+0.33%	-1.20%	+3.03%	-9.06%	-36.03%
NVS Novartis	+0.65%	+2.99%	+4.68%	+10.58%	+13.73%
PFE Pfizer	+0.31%	+0.96%	+3.45%	-1.04%	-13.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9418 of 5 stars	3.4	5.0	4.2	3.9	2.9	1.7	1.3
ABT Abbott Laboratories	4.8969 of 5 stars	2.4	3.0	4.2	4.5	2.9	2.5	2.5
MRK Merck & Co., Inc.	4.9963 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVS Novartis	1.6116 of 5 stars	1.0	3.0	2.5	0.0	2.8	0.0	1.9
PFE Pfizer	4.879 of 5 stars	2.3	3.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.25% Upside
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	4.70% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	33.56% Upside
NVS Novartis	2.00	Hold	$123.38	0.26% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	16.53% Upside

Current Analyst Ratings Breakdown

Latest ABT, ABBV, PFE, MRK, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.96	$15.28 per share	12.43	$1.90 per share	99.96
ABT Abbott Laboratories	$41.95B	5.65	$6.59 per share	20.66	$27.62 per share	4.93
MRK Merck & Co., Inc.	$64.17B	3.20	$9.78 per share	8.36	$18.33 per share	4.46
NVS Novartis	$50.32B	5.17	$10.88 per share	11.31	$21.59 per share	5.70
PFE Pfizer	$63.63B	2.24	$4.51 per share	5.55	$15.62 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.82	13.59	1.23	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
ABT Abbott Laboratories	$13.40B	$7.71	17.67	23.77	2.58	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.90	8.26	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.23	13.97	1.74	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.14	8.26	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest ABT, ABBV, PFE, MRK, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.45%	N/A	279.15%	53 Years
ABT Abbott Laboratories	$2.36	1.73%	N/A	30.61%	54 Years
MRK Merck & Co., Inc.	$3.24	3.96%	N/A	47.16%	14 Years
NVS Novartis	$2.60	2.11%	N/A	40.63%	N/A
PFE Pfizer	$1.72	6.87%	N/A	124.64%	16 Years

Latest ABT, ABBV, PFE, MRK, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
ABT Abbott Laboratories	0.26	1.78	1.27
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ABT Abbott Laboratories	0.46%
MRK Merck & Co., Inc.	0.09%
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

ABT, ABBV, PFE, MRK, and NVS Headlines

Recent News About These Companies

Pfizer scientist subpoenaed over claims COVID vax testing was ‘deliberately’ slowed before 2020 election

July 1 at 4:52 PM | msn.com

Pfizer (NYSE:PFE) Trading 3.3% Higher - What's Next?

July 1 at 3:40 PM | marketbeat.com

Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition

July 1 at 3:16 PM | seekingalpha.com

Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth

July 1 at 11:06 AM | globenewswire.com

Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth

July 1 at 10:36 AM | zacks.com

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

July 1 at 10:01 AM | zacks.com

Sumitomo Mitsui DS Asset Management Company Ltd Has $19.82 Million Holdings in Pfizer Inc. (NYSE:PFE)

July 1 at 8:38 AM | marketbeat.com

BLB&B Advisors LLC Sells 25,375 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 8:09 AM | marketbeat.com

Alta Advisers Ltd Buys 13,100 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 7:05 AM | marketbeat.com

Hixon Zuercher LLC Acquires 14,753 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 6:47 AM | marketbeat.com

326,865 Shares in Pfizer Inc. (NYSE:PFE) Purchased by CHURCHILL MANAGEMENT Corp

July 1 at 6:30 AM | marketbeat.com

Pfizer (NYSE:PFE) Expands Collaboration With XtalPi To Enhance Drug Discovery Platform

July 1 at 4:42 AM | finance.yahoo.com

US House committee subpoenas former Pfizer executive over alleged COVID vaccine delay

June 30 at 4:52 PM | investing.com

House committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports

June 30 at 4:01 PM | reuters.com

Pfizer’s Promising Phase 3 Study on Prostate Cancer Treatment: A Potential Game Changer

June 30 at 12:15 PM | tipranks.com

Pfizer’s Sayana Press Study: Optimizing Drug Delivery for Better Outcomes

June 30 at 12:15 PM | tipranks.com

Essex LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 30 at 9:04 AM | marketbeat.com

First Fiduciary Investment Counsel Inc. Buys 40,783 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 8:40 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Argent Advisors Inc.

June 30 at 7:58 AM | marketbeat.com

New York State Teachers Retirement System Sells 142,670 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 6:41 AM | marketbeat.com

Amalgamated Bank Purchases 16,085 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 6:22 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABT, ABBV, PFE, MRK, and NVS Company Descriptions

AbbVie NYSE:ABBV

$189.92 +4.30 (+2.32%)

Closing price 03:59 PM Eastern

Extended Trading

$189.86 -0.06 (-0.03%)

As of 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$136.21 +0.20 (+0.15%)

Closing price 03:59 PM Eastern

Extended Trading

$135.91 -0.30 (-0.22%)

As of 07:59 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Merck & Co., Inc. NYSE:MRK

$81.75 +2.59 (+3.27%)

Closing price 03:59 PM Eastern

Extended Trading

$82.02 +0.27 (+0.33%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$123.06 +2.05 (+1.69%)

Closing price 03:59 PM Eastern

Extended Trading

$123.11 +0.05 (+0.04%)

As of 07:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.03 +0.79 (+3.26%)

Closing price 03:59 PM Eastern

Extended Trading

$25.07 +0.04 (+0.18%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time